Delcath Systems, Inc. Common Stock (DCTH) Stock
Key stats
- Market cap
- $757.34M
- Price / Earnings ratio
- 105.1x
- EPS (TTM)
- $0.18
- Volume
- Loading
- 52-week high
- $21.84
- 52-week low
- $8.12
Source: third-party data provider, as of November 13, 2026
Compare with DCTH
Recent news

Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems to Participate in Upcoming Investor Conferences
DCTH

Delcath Systems to Host Third Quarter 2026 Earnings Call
Delcath Systems to Host Third Quarter 2026 Earnings Call
DCTH

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
DCTH

3 Emerging Biotech Stocks With Significant Upside Potential
3 Emerging Biotech Stocks With Significant Upside Potential
DCTH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 81.60
- MACD 12/26/9
- 1.00
- EMA 9 of MACD
- 0.18
- MACD histogram
- 0.81
- SMA 50
- $15.71
- Price above SMA 50
- EMA 50
- $15.62
- Price above EMA 50
- SMA 200
- $12.60
- Price above SMA 200
- EMA 200
- $12.95
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems to Participate in Upcoming Investor Conferences
DCTH

Delcath Systems to Host Third Quarter 2026 Earnings Call
Delcath Systems to Host Third Quarter 2026 Earnings Call
DCTH

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
DCTH

3 Emerging Biotech Stocks With Significant Upside Potential
3 Emerging Biotech Stocks With Significant Upside Potential
DCTH

Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?
Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?
DCTH

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DCTH

Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH
Keep Portfolio Volatility in Check With VLO, PBF, FET & DCTH
DCTH

5 Stocks With Recent Price Strength Buoyed by a Strong August
5 Stocks With Recent Price Strength Buoyed by a Strong August
DCTH

Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems to Participate in Upcoming Investor Conferences
DCTH

What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?
What Makes Delcath Systems, Inc. (DCTH) a Strong Momentum Stock: Buy Now?
DCTH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Delcath Systems, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Gerard J. Michel MBA, MS | CEO & Director | 1963 |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer | 1970 |
| Ms. Sandra Pennell C.P.A. | Chief Financial Officer | 1979 |
| Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. | Chief Medical Officer | 1967 |
| Mr. David Hoffman J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 1970 |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 1964 |
| Mr. Kevin Muir | Chief Commercial Officer | — |
| Dr. Michael Brunner M.D. | Senior Vice President of Interventional Oncology | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 81.60
- MACD 12/26/9
- 1.00
- EMA 9 of MACD
- 0.18
- MACD histogram
- 0.81
- SMA 50
- $15.71
- Price above SMA 50
- EMA 50
- $15.62
- Price above EMA 50
- SMA 200
- $12.60
- Price above SMA 200
- EMA 200
- $12.95
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $25.00
- Average
- $30.50
- High
- $36.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.4 | -20.2 | ||||||||||
| 2022 | -13.2 | -6.6 | +4.1 | -3.4 | -21.2 | -11.1 | +6.9 | +0.0 | -21.6 | -11.9 | -0.3 | +25.0 |
| 2023 | +7.8 | +33.7 | +18.8 | -3.2 | +37.5 | -22.4 | -21.6 | +9.3 | -16.7 | -15.5 | -11.6 | +44.4 |
| 2024 | +16.5 | -11.7 | +13.8 | +8.6 | +30.6 | +24.4 | +4.4 | +34.3 | -14.5 | +22.9 | +13.1 | -4.7 |
| 2025 | +23.7 | -8.3 | -4.6 | -4.2 | +34.2 | -16.6 | -15.8 | +4.1 | -1.4 | -8.6 | +1.9 | +5.4 |
| 2026 | -0.4 | -10.8 | +3.9 | +8.8 | -0.2 | +18.8 | -5.3 | +26.2 | -2.6 | -8.9 | +52.3 |



